Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly.
Up this week:  
The good — Amneal gets FDA nod for Parkinson’s pill 
The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure 
The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy

FDA approves Ascendis drug, Lykos PTSD treatment rejected, Novartis bid blocked [The good, the bad, the ugly]

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more

Podbean

Off Script: A Pharma Manufacturing Podcast

FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly]

Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly]